FDA Approves Qfitlia™ – New Treatment Option for Hemophilia A & B

The FDA has approved Sanofi’s Qfitlia™ (fitusiran), a new subcutaneous therapy for people with hemophilia A or B, with or without inhibitors. This innovative treatment uses siRNA technology to target antithrombin, offering less frequent dosing than existing options. Learn more about this significant advancement for patients ages 12 and older.

Source: National Bleeding Disorders Foundation (April 2025)